| B11 | Long-term survival and predictors of mortality in HIV/TB patients in Uganda | On-demand oral abstract session | Tuberculosis and other mycobacteria |
| B68 | Incidence and co-factors of Mtb infection in first 2 years of life: observational follow-up of a randomized controlled trial of INH to prevent primary Mtb infection among HIV-exposed uninfected children | On-demand oral abstract session | HIV-exposed uninfected children |
| B35 | Comparison of viral replication for the 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC) versus a 3/4-drug tenofovir alafenamide'based regimen (TBR) in the TANGO study through week 96 | On-demand oral abstract session | Regimen simplification and switch studies |
| B39 | Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) | On-demand oral abstract session | Long-acting agents and other drug delivery systems |
| B35 | Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naïve patients | On-demand oral abstract session | Regimen simplification and switch studies |
| B43 | Islatravir safety analysis through week 96 from a phase 2 trial in treatment naïve adults with HIV-1 infection | On-demand oral abstract session | New strategies (2DR, rapid start) |
| B45 | New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virus | On-demand oral abstract session | Immune-based therapy trials |
| B9 | Is systematic Xpert MTB/RIF improved the detection of tuberculosis in HIV-infected patients in a low tuberculosis incidence setting in West Africa? | On-demand oral abstract session | Diagnosis of co-infections and co-morbidities |
| B9 | The point of care device needed for confirming active hepatitis C infection in the prison population | On-demand oral abstract session | Diagnosis of co-infections and co-morbidities |
| B8 | Plasma separation cards are suitable for HIV-1 genotypic drug resistance testing | On-demand oral abstract session | Drug resistance testing |